| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vascular Biology |
From the Departments of Veterinary Pharmacology (T.M., K.K., M.H., H.K., H.O.) and Comparative Pathophysiology (M.K., H.T.), Graduate School of Agriculture and Life Sciences, The University of Tokyo, Japan.
Correspondence to Takahisa Murata, DVM, PhD, Department of Veterinary Pharmacology, Graduate School of Agriculture, and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan. E-mail murata{at}mail.vm.a.u-tokyo.ac.jp
Objective We investigated the effects of fluvastatin on hypoxia-induced (1 to 3 weeks, 10% O2) pulmonary hypertension with focus on endothelial nitric oxide synthase (eNOS) activity.
Methods and Results Oral fluvastatin treatment (1 mg/kg daily) prevented the causing and progression of pulmonary hypertension as determined by the right ventricular pressure, right ventricular hypertrophy, and muscularization of pulmonary artery. We also revealed that fluvastatin treatments prevented the hypoxia-induced decrease in cGMP production in the rat lung and restored the endothelium-dependent relaxation in the pulmonary artery. We revealed that this beneficial effect was not dependent on the increase in eNOS mRNA or protein expression, but was dependent on the inhibition of the eNOS-tight coupling with caveolin-1, the eNOS dissociation from heat shock protein 90, and the decrease in eNOS Ser1177phosphorylation induced by hypoxia. Furthermore, in a whole-mount immunostaining the hypoxia-induced eNOS protein condensation with caveolin-1 of pulmonary endothelial cells was restored by the fluvastatin-treatment.
Conclusion These results suggest that the fluvastatin exerts beneficial effects on chronic hypoxia-induced pulmonary hypertension by protecting against the eNOS activity at the post-transcriptional level.
We investigated the effect of fluvastatin on endothelial impairment in pulmonary hypertension and revealed that fluvastatin can restore the decrease in endothelial NO production through its protective effects against eNOS-tight coupling with caveolin-1 caused by chronic hypoxia.
Key Words: endothelial nitric oxide synthase fluvastatin hypoxia
This article has been cited by other articles:
![]() |
N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shao, Y. Tan, D. Eton, Z. Yang, M. G. Uberti, S. Li, A. Schulick, and H. Yu Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis by Enhancement of Progenitor Cells Incorporation into New Vessels Stem Cells, May 1, 2008; 26(5): 1376 - 1384. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Du, Y.-Y. Guan, N. J. Alp, K. M. Channon, and A. F. Chen Endothelium-Specific GTP Cyclohydrolase I Overexpression Attenuates Blood Pressure Progression in Salt-Sensitive Low-Renin Hypertension Circulation, February 26, 2008; 117(8): 1045 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Sun and D. D. Ku Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H801 - H809. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pokreisz, G. Marsboom, and S. Janssens Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H75 - H84. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Carlin, A. J. Peacock, and D. J. Welsh Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 447 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Laudi, S. Trump, V. Schmitz, J. West, I. F. McMurtry, H. Mutlak, U. Christians, J. Weimann, U. Kaisers, and W. Steudel Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L630 - L638. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Girgis, S. Mozammel, H. C. Champion, D. Li, X. Peng, L. Shimoda, R. M. Tuder, R. A. Johns, and P. M. Hassoun Regression of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1105 - L1110. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |